PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27645339-9	2016	The risk of disability progression (3-month) was reduced by 19-28% with interferon-beta products, glatiramer acetate, fingolimod and teriflunomide, by 38-45% for pegylated interferon-beta, dimethyl fumarate and natalizumab and by 68% with alemtuzumab.	Dimethyl Fumarate	189-206	interferon beta 1	Homo sapiens	72-87	
28906152-11	2017	Among treatment-naive patients, those receiving DMF had 2.4-times the risk (HR = 2.439, 95% CI = 1.007-5.917, p = .0483) of experiencing a discontinuation than patients receiving sc IFN beta-1a.	Dimethyl Fumarate	48-51	interferon beta 1	Homo sapiens	182-190	
28906152-12	2017	Non-persistent patients receiving DMF had 2.3-times the risk (HR = 2.311, 95% CI = 1.350-3.958, p = .0023) of experiencing an adverse event at a given time point than patients prescribed sc IFN beta-1a.	Dimethyl Fumarate	34-37	interferon beta 1	Homo sapiens	190-198	
28751099-2	2017	Post hoc analyses of integrated data from DEFINE/CONFIRM were conducted to evaluate the effect of DMF in patients previously treated with interferon (IFN) beta.	Dimethyl Fumarate	98-101	interferon beta 1	Homo sapiens	138-159	
28211024-7	2017	Compared with DMF, the adjusted IRR (95% CI) for relapse in the year after initiating therapy was 1.27 (1.10-1.46) for IFNbeta, 1.34 (1.17-1.53) for GA, 1.23 (1.05-1.45) for teriflunomide, and 1.03 (0.88-1.21) for fingolimod.	Dimethyl Fumarate	14-17	interferon beta 1	Homo sapiens	119-126	
24759080-4	2014	RECENT FINDINGS: Recent large placebo-controlled trials in relapsing-remitting multiple sclerosis have shown efficacy of new oral disease-modifying drugs, teriflunomide and dimethyl fumarate, with similar or better efficacy than the injectable disease-modifying drugs, IFN-beta and glatiramer acetate.	Dimethyl Fumarate	173-190	interferon beta 1	Homo sapiens	269-277	
27252601-0	2016	Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.	Dimethyl Fumarate	43-60	interferon beta 1	Homo sapiens	79-94	
27252601-2	2016	The objective of this study was to explore the safety and tolerability of DMF when administered with interferon beta (IFNbeta) or glatiramer acetate (GA).	Dimethyl Fumarate	74-77	interferon beta 1	Homo sapiens	101-116	
25182864-2	2014	Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS.	Dimethyl Fumarate	236-253	interferon beta 1	Homo sapiens	69-77